EXECUTIVE TEAM JON PILCHER Chief Executive Officer/Managing Director BSc (Hons), FCA Jon joined Neuren in 2013 as CFO and was appointed CEO in May 2020. He has played a central role in all aspects of Neuren’s R&D, commercial and corporate activities. Before joining Neuren he was a member of the leadership team at Acrux throughout a period that included Acrux’s IPO and listing on the ASX, the development and FDA approval of three novel pharmaceutical products and a transforming licensing deal with Eli Lilly in 2010. He formerly spent seven years in a series of executive positions in the R&D and corporate functions of international pharmaceutical groups Medeva and Celltech, which are now part of UCB. Jon is a Chartered Accountant and holds a degree in Biotechnology from the University of Reading in the UK. LARRY GLASS Chief Science Officer BA (Biology) Larry joined Neuren in 2004 and was an Executive Director from 2012 to 2018. He directs Neuren’s scientific and non-clinical development, as well as playing a leading role in clinical and regulatory strategy. Larry has more than 30 years’ experience in the life sciences industry, including clinical trials, basic and applied research, epidemiologic studies, diagnostics and pharmaceutical product development. Before he joined Neuren, he worked as an independent consultant for a number of biotech companies in the US and internationally provided management, strategic and business development services. Prior to that, he was CEO of a contract research organisation that provided preclinical research and clinical trials support for major pharmaceutical and biotechnology companies and the US government. Larry is a biologist with additional graduate training in epidemiology and biostatistics. LIZA SQUIRES, M.D. Chief Medical Officer Liza joined Neuren in 2022 and leads the medical, clinical and regulatory aspects of Neuren’s development programs. Liza is a board certified physician in General Pediatrics and Neurology with Special Competence in Child Neurology. Over the past 20 years, she has held positions of increasing responsibilities in both early and late-stage drug development at Johnson and Johnson, Shire Pharmaceuticals, Lumos Pharma, Aevi Genomic Medicine and Origin Biosciences. She has led and contributed to multiple New Drug Applications resulting in global regulatory approvals and has extensive experience in orphan drug development. Liza received her B.S. from the University of Michigan and M.D. from Michigan State University. She trained in general pediatrics at Yale University and did her residency in Child Neurology at Massachusetts General Hospital. DARYL DEKARSKE Chief Regulatory Officer M.P.H Daryl joined Neuren in May 2025. He brings almost 30 years of experience in the biopharmaceutical industry, most recently from the rare disease company Horizon Therapeutics, where he served as Sr. Vice President of Global Regulatory Affairs. Previous to Horizon Therapeutics, Daryl led Global Regulatory Affairs and Translation Sciences for Acadia Pharmaceuticals, where he was instrumental in the Phase 3 development and NDA supporting the FDA approval of trofinetide. Daryl also held regulatory affairs and product development leaderships roles at Shire, Sanofi and Searle-Pharmacia in multiple therapeutic areas, including CNS, and across drug, biologic and cell-therapy technologies. Earlier in his career, Daryl conducted clinical and nonclinical toxicology research for SmithKline Beecham Corporation and Parke-Davis and Company, respectively. Daryl earned his B.S. in Microbiology and Master in Public Health in Toxicology from the University of Michigan. Neuren Pharmaceuticals Limited Annual Report 2025 22
RkJQdWJsaXNoZXIy MjE2NDg3